ECMO or ventilator use was the most significant predictor of mortality in patients undergoing lung transplant for idiopathic ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...